- DecisionDx-Melanoma test by Castle Biosciences reduces mortality risk by 32% compared to untested patients.
- The study involved over 13,500 patients, marking the largest real-world study of gene expression profile testing.
- New uveal melanoma test shows 91% sensitivity and 92% negative predictive value through liquid biopsy.
Castle Biosciences (CSTL, Financial) is set to present groundbreaking research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Their DecisionDx-Melanoma test demonstrated a significant 32% reduction in mortality risk compared to those who were not tested. The study, which included a cohort of over 13,500 patients, is the largest real-world investigation of gene expression profile testing to date.
The DecisionDx-Melanoma test provides enhanced risk stratification, surpassing the conventional American Joint Committee on Cancer (AJCC) staging. The findings showed a hazard ratio of 4.59 in Class 2B patients and 3.42 in Class 1B/2A patients, with both values being statistically significant (p<0.001).
In addition, Castle Biosciences will reveal results related to their new 16-protein test designed for uveal melanoma using a minimally invasive liquid biopsy approach. This innovative test has shown a sensitivity of 91% and a negative predictive value of 92% in distinguishing between low and high-risk uveal melanoma lesions.
The presentations will occur during the Melanoma/Skin Cancers poster session on June 1, 2025, providing deeper insights into the test's potential to inform more precise and individualized treatment pathways, ultimately aiming to improve patient outcomes significantly.
